Roflumilast is safe and effective in improving symptoms and lung function in severe COPD
AbstractThe case of a 66-year-old man with severe chronic obstructive pulmonary disease (COPD) is presented. Diagnosis was based on baseline pulmonary function tests (PFTs) and clinical examination. Therapy with tiotropium 18 Î¼g (once daily) and salmeterol/fluticasone 50/500 Î¼g (twice daily) failed to achieve optimal disease control. Roflumilast (Daxas) 500 Î¼g once daily was therefore added and a progressive improvement in the patientâ€™s condition was observed during the 1-year followup. In this patient with severe COPD, roflumilast represented a safe and effective therapeutic strategy for managing clinical symptoms and for significantly improving lung function parameters.
- Abstract views: 467
- PDF: 450
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.